Global Non-Hodgkin Lymphoma Therapeutics Market Value to Hit $9.2 Billion by 2020
The global Non-Hodgkin Lymphoma (NHL) treatment market will increase in value from $5.6 billion in 2013 to $9.2 billion by 2020, representing a compound annual growth rate (CAGR) of 7.4%, says business intelligence provider GBI Research.
The company’s latest report* states that high unmet clinical needs and the launch of promising drugs will be key global drivers, although the patent expiry of blockbuster Rituxan in the EU will hinder market growth in this region.
According to Sravanthi Addapally, Analyst for GBI Research, while Rituxan has dramatically improved NHL patient prognosis and been the standard of care in front-line treatment regimens and also in maintenance settings, there is increasing evidence of rituximab resistance.
Addapally explains: “Overcoming rituximab resistance has been a major focus of recent therapeutic development. This treatment challenge will create space for the entry of three promising new therapies, which will ultimately drive NHL market growth.
“Following their anticipated launches, the second generation anti-CD20 monoclonal Antibody (mAb), ofatumumab, and the third generation anti-CD20 mAb, obinutuzumab, may be able to induce stronger complement-dependent cytotoxicity in rituximab-resistant cell lines. Additionally, the immunotherapeutic vaccine dasiprotimut-T has the potential to eliminate the risk of rituximab resistance.”
While these product launches will have a positive impact on the market, Rituxan, or Mabthera in the EU, is set to lose its patent exclusivity in this region by the end of 2014, limiting further growth.
Addapally comments: “Mabthera, which was initially approved by the European Medicines Agency in 1998 for relapsed or refractory low-grade or follicular NHL, gained a number of line extensions and is currently approved for many NHL sub-types. A new subcutaneous formulation of Mabthera has also been approved in the EU.
“While Mabthera is expected to retain its superior share of the NHL treatment space, the cost decrease following the drug’s patent expiry will be the prime reason for the flat market in the EU.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance